rcb1

Otenabant hydrochloride (Otenabant) (CP-945598) is a competitive, high affinity, selective antagonist of the CB1 receptor (Ki: 0.7 nM).

RCB18350 is an antituberculosis agent and an isoxazole derivative. It demonstrates bacteriostatic properties by inhibiting the growth of Mycobacterium tuberculosis, with a minimum inhibitory concentration (MIC) of 1.25 μg/mL. RCB18350 is effective against multi-drug resistant Mycobacterium tuberculosis (MDR-TB) clinical isolates, Mycobacterium bovis BCG, and Mycobacterium avium, all of which are slow-growing mycobacteria.

RCB16007 is a Yellow Fever Virus (YFV) inhibitor that exhibits inhibitory action against the West Nile virus with an effective concentration (EC50) of 7.9 μM and a cytotoxic concentration (CC50) of 17 μM [1].

Drinabant (AVE-1625) is an orally active CB1 receptor antagonist. Drinabant inhibits the agonist-stimulated calcium signal with IC50 values of 25 nM and 10 nM for the hCB1-R and rCB1-R, respectively, and is ineffective for the hCB2-R.

AM8936 is a well-balanced and highly potent agonist for the cannabinoid receptor type-1 (CB1) in functional assays, with EC50 values of 8.6 nM and 1.4 nM for the rat CB1 (rCB1) and human CB1 (hCB1) receptors, respectively. It demonstrates a strong affinity for the rat CB1 receptor, exhibiting a K i value of 0.55 nM. In vivo studies have confirmed that AM8936 is a powerful and effective agonist for the CB1 receptor. Due to its therapeutic potential, AM8936 is particularly valuable for research focused on central nervous system disorders, metabolic disorders, pain management, glaucoma, and other related areas [1].